Development of AAV-Based CRISPR/Cas9 Therapies for Correcting Duchenne Muscular Dystrophy by Targeted Genomic Integration
Publication
, Conference
Oliver, A; Nelson, C; Bohning, J; Gilcrest, K; Gersbach, C
Published in: MOLECULAR THERAPY
2020
Duke Scholars
Published In
MOLECULAR THERAPY
EISSN
1525-0024
ISSN
1525-0016
Publication Date
2020
Volume
28
Issue
4
Start / End Page
6 / 6
Related Subject Headings
- Biotechnology
- 3206 Medical biotechnology
- 3202 Clinical sciences
- 3105 Genetics
- 11 Medical and Health Sciences
- 10 Technology
- 06 Biological Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Oliver, A., Nelson, C., Bohning, J., Gilcrest, K., & Gersbach, C. (2020). Development of AAV-Based CRISPR/Cas9 Therapies for Correcting Duchenne Muscular Dystrophy by Targeted Genomic Integration. In MOLECULAR THERAPY (Vol. 28, pp. 6–6).
Oliver, Adrian, Christopher Nelson, Joel Bohning, Kylie Gilcrest, and Charles Gersbach. “Development of AAV-Based CRISPR/Cas9 Therapies for Correcting Duchenne Muscular Dystrophy by Targeted Genomic Integration.” In MOLECULAR THERAPY, 28:6–6, 2020.
Oliver A, Nelson C, Bohning J, Gilcrest K, Gersbach C. Development of AAV-Based CRISPR/Cas9 Therapies for Correcting Duchenne Muscular Dystrophy by Targeted Genomic Integration. In: MOLECULAR THERAPY. 2020. p. 6–6.
Oliver, Adrian, et al. “Development of AAV-Based CRISPR/Cas9 Therapies for Correcting Duchenne Muscular Dystrophy by Targeted Genomic Integration.” MOLECULAR THERAPY, vol. 28, no. 4, 2020, pp. 6–6.
Oliver A, Nelson C, Bohning J, Gilcrest K, Gersbach C. Development of AAV-Based CRISPR/Cas9 Therapies for Correcting Duchenne Muscular Dystrophy by Targeted Genomic Integration. MOLECULAR THERAPY. 2020. p. 6–6.
Published In
MOLECULAR THERAPY
EISSN
1525-0024
ISSN
1525-0016
Publication Date
2020
Volume
28
Issue
4
Start / End Page
6 / 6
Related Subject Headings
- Biotechnology
- 3206 Medical biotechnology
- 3202 Clinical sciences
- 3105 Genetics
- 11 Medical and Health Sciences
- 10 Technology
- 06 Biological Sciences